“We have raised our long-term forecasts for Alimta ex US revenues on higher confidence that the EU patent should hold until 2020 (from current assumption of 2015), per recent external patent counsel review. … Alimta’s existing key patent expirations in most major European countries include both the compound patent (2015) and the vitamin dosage regimen patent (2021). Upon review of the initial EU ruling, external patent counsel believes the decision is solid and unlikely to be reversed, while commenting on the decision’s lack of requirement for claim amendments as further evidence to the patent’s integrity.,” Credit Suisse’s analyst wrote.
Eli Lilly & Co. traded down 0.15% on Wednesday, hitting $54.58. Eli Lilly & Co. has a 52-week low of $38.56 and a 52-week high of $54.99. The stock’s 50-day moving average is currently $53.68. The company has a market cap of $59.691 billion and a price-to-earnings ratio of 14.93.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet reiterated a buy rating on shares of Eli Lilly & Co. in a research note to investors on Tuesday. Separately, analysts at Jefferies Group reiterated an underperform rating on shares of Eli Lilly & Co. in a research note to investors on Monday. They now have a $43.00 price target on the stock. Finally, analysts at Jefferies Group reiterated an underperform rating on shares of Eli Lilly & Co. in a research note to investors on Friday, February 15th. They now have a $43.00 price target on the stock.
Five research analysts have rated the stock with a buy rating, two have issued an overweight rating, twelve have issued a hold rating, and three have given a sell rating to the stock. Eli Lilly & Co. presently has a consensus rating of hold and an average target price of $54.93.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.